Journal For Clinical Studies
Journal For Clinical Studies

SEARCH

MEDIA PACK
NEWS

MENU

Current Edition

 
clinical trial

Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer

Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that TG02 has passed the initial …

20 December 2017 news clinical trial immuno-oncology
Continue Reading →
antibody

Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from a pivotal Phase 2 clinical study of cemiplimab in 82 patients with …

13 December 2017 news antibody BLA
Continue Reading →
immuno-oncology

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the …

13 December 2017 news immuno-oncology mesothelioma
Continue Reading →
 
jcs-white

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Twitter Linkedin
Journal For Clinical Studies © 2022, All Rights Reserved – Powered by Teksyte